Hepatitis B virus reactivation with rituximab-containing regimen

World Journal of Hepatology

Volumn 5, Issue 11, 2013, Pages 612-620

  Tsutsumi, Yutaka ^a   Yamamoto, Yoshiya ^a   Shimono, Joji ^a   Ohhigashi, Hiroyuki ^a   Teshima, Takanori ^b  

^a Hakodate Municipal Hospital   (Japan)

^b HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Chemotherapy; Hepatitis B virus; Lamivudine; Non Hodgkin's lymphoma; Reactivation; Rituximab

Indexed keywords

EID: 84890636076     PISSN: None     EISSN: 19485182     Source Type: Journal    
DOI: 10.4254/wjh.v5.i11.612     Document Type: Short Survey

References (77)

1. Maloney DG, Liles TM, Czerwinski DK, Waldichuk C, Rosenberg J, Grillo-Lopez A, Levy R. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 1994; 84: 2457-2466 [PMID: 7522629]
2. Maloney DG, Grillo-López AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA, Janakiraman N, Foon KA, Liles TM, Dallaire BK, Wey K, Royston I, Davis T, Levy R. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphom a. Blood 1997; 90: 2188-2195 [PMID: 9310469]
3. Maloney DG, Grillo-López AJ, Bodkin DJ, White CA, Liles TM, Royston I, Varns C, Rosenberg J, Levy R. IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol 1997; 15: 3266-3274 [PMID: 9336364]
4. Bermúdez A, Marco F, Conde E, Mazo E, Recio M, Zubizarreta A. Fatal visceral varicella-zoster infection following rituximab and chemotherapy treatment in a patient with follicular lymphoma. Haematologica 2000; 85: 894-895 [PMID: 10942955]
5. Sharma VR, Fleming DR, Slone SP. Pure red cell aplasia due to parvovirus B19 in a patient treated with rituximab. B lood 2000; 96: 1184-1186 [PMID: 10910942]
6. Suzan F, Ammor M, Ribrag V. Fatal reactivation of cytomegalovirus infection after use of rituximab for a posttransplantation lymphoproliferative disorder. N Engl J Med 2001; 345: 1000 [PMID: 11575282 DOI: 10.1056/ NEJM200109273451315]
7. Goldberg SL, Pecora AL, Alter RS, Kroll MS, Rowley SD, Waintraub SE, Imrit K, Preti RA. Unusual viral infections (progressive multifocal leukoencephalopathy and cytomegalovirus disease) after high-dose chemotherapy with autologous blood stem cell rescue and peritransplantation rituximab. Blood 2002; 99: 1486-1488 [PMID: 11830505 DOI: 10.1182/blood.V99.4.1486]
8. Galbraith RM, Eddleston AL, Williams R, Zuckerman AJ. Fulminant hepatic failure in leukaemia and choriocarcinoma related to withdrawal of cytotoxic drug therapy. Lancet 1975; 2: 528-530 [PMID: 51345]
9. Hoofnagle JH, Dusheiko GM, Schafer DF, Jones EA, Micetich KC, Young RC, Costa J. Reactivation of chronic hepatitis B virus infection by cancer chemotherapy. Ann Intern Med 1982; 96: 447-449 [PMID: 7065560 DOI: 10.7326/0003-48 19-96-4-447]
10. Thung SN, Gerber MA, Klion F, Gilbert H. Massive hepatic necrosis after chemotherapy withdrawal in a hepatitis B virus carrier. Arch Intern Med 1985; 145: 1313-1314 [PMID: 4015284 DOI: 10.1001/archinte.1985.00360070195034]
11. Lau JY, Lai CL, Lin HJ, Lok AS, Liang RH, Wu PC, Chan TK, Todd D. Fatal reactivation of chronic hepatitis B virus infection following withdrawal of chemotherapy in lymphoma patients. Q J Med 1989; 73: 911-917 [PMID: 2629023]
12. Liang RH, Lok AS, Lai CL, Chan TK, Todd D, Chiu EK. Hepatitis B infection in patients with lymphomas. Hematol Oncol 1990; 8: 261-270 [PMID: 1701155 DOI: 10.1002/ hon.2900080504]
13. Tsutsumi Y, Kanamori H, Mori A, Tanaka J, Asaka M, Imamura M, Masauzi N. Reactivation of hepatitis B virus with rituximab. Expert Opin Drug Saf 2005; 4: 599-608 [PMID: 15934864 DOI: 10.1517/14740338.4.3.599]
14. Tsutsumi Y, Shigematsu A, Hashino S, Tanaka J, Chiba K, Masauzi N, Kobayashi H, Kurosawa M, Iwasaki H, Morioka M, Asaka M, Imamura M. Analysis of reactivation of hepatitis B virus in the treatment of B cell non-Hodgkin's lymphoma in Hokkaido. Ann Hematol 2009; 88: 375-377 [PMID: 18726097 DOI: 10.1007/s00277-008-0585-6]
15. Skrabs C, Müller C, Agis H, Mannhalter C, Jäger U. Treat-ment of HBV-carrying lymphoma patients with Rituximab and CHOP: a diagnostic and therapeutic challenge. Leukemia 2002; 16: 1884-1886 [PMID: 12200717 DOI: 10.1038/ sj.leu.2402567]
16. Westhoff TH, Jochimsen F, Schmittel A, Stoffler-Meilicke M, Schafer JH, Zidek W, Gerlich WH, Thiel E. Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapy. Blood 2003; 102: 1930 [PMID: 12930732 DOI: 10.1182/blood-2003-05-1403]
17. Dervite I, Hober D, Morel P. Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab. N Engl J Med 2001; 344: 68-69 [PMID: 11187122 DOI: 10.1056/NEJM200101043440120]
18. Ng HJ, Lim LC. Fulminant hepatitis B virus reactivation with concomitant listeriosis after fludarabine and rituximab therapy: case report. Ann Hematol 2001; 80: 549-552 [PMID: 11669307 DOI: 10.1007/s002770100346]
19. Jäeger G, Neumeister P, Brezinschek R, Höfler G, Quehenberger F, Linkesch W, Sill H. Rituximab (anti-CD20 monoclonal antibody) as consolidation of first-line CHOP chemotherapy in patients with follicular lymphoma: a phase II study. Eur J Haematol 2002; 69: 21-26 [PMID: 12270058 DOI: 10.1034/j.1600-0609.2002.01692.x]
20. Tsutsumi Y, Kawamura T, Saitoh S, Yamada M, Obara S, Miura T, Kanamori H, Tanaka J, Asaka M, Imamura M, Masauzi N. Hepatitis B virus reactivation in a case of non-Hodgkin's lymphoma treated with chemotherapy and rituximab: necessity of prophylaxis for hepatitis B virus reactivation in rituximab therapy. Leuk Lymphoma 2004; 45: 627-629 [PMID: 15160930 DOI: 10.1080/1042819031000151923]
21. Tsutsumi Y, Tanaka J, Kawamura T, Miura T, Kanamori H, Obara S, Asaka M, Imamura M, Masauzi N. Possible efficacy of lamivudine treatment to prevent hepatitis B virus reactivation due to rituximab therapy in a patient with non-Hodgkin's lymphoma. Ann Hematol 2004; 83: 58-60 [PMID: 14513286 DOI: 10.1007/s00277-003-0748-4]
22. Yang SH, Kuo SH. Reactivation of hepatitis B virus during rituximab treatment of a patient with follicular lymphoma. Ann Hematol 2008; 87: 325-327 [PMID: 17932671 DOI: 10.1007/s00277-007-0396-1]
23. Guidotti LG, Rochford R, Chung J, Shapiro M, Purcell R, Chisari FV. Viral clearance without destruction of infected cells during acute HBV infection. Science 1999; 284: 825-829 [PMID: 10221919 DOI: 10.1126/science.284.5415.825]
24. Webster GJ, Reignat S, Maini MK, Whalley SA, Ogg GS, King A, Brown D, Amlot PL, Williams R, Vergani D, Dusheiko GM, Bertoletti A. Incubation phase of acute hepatitis B in man: dynamic of cellular immune mechanisms. Hepatology 2000; 32: 1117-1124 [PMID: 11050064 DOI: 10.1053/ jhep.2000.19324]
25. Lok AS, Liang RH, Chiu EK, Wong KL, Chan TK, Todd D. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology 1991; 100: 182-188 [PMID: 1983820]
26. Nakamura Y, Motokura T, Fujita A, Yamashita T, Ogata E. Severe hepatitis related to chemotherapy in hepatitis B virus carriers with hematologic malignancies. Survey in Japan, 1987-1991. Cancer 1996; 78: 2210-2215 [PMID: 8918416]
27. Kumagai K, Takagi T, Nakamura S, Sawada U, Kura Y, Kodama F, Shimano S, Kudoh I, Nakamura H, Sawada K, Ohnoshi T. Hepatitis B virus carriers in the treatment of malignant lymphoma: an epidemiological study in Japan. Ann Oncol 1997; 8 Suppl 1: 107-109 [PMID: 9187442 DOI: 10.1093/annonc/8.suppl_1.S107]
28. Yeo W, Chan PK, Zhong S, Ho WM, Steinberg JL, Tam JS, Hui P, Leung NW, Zee B, Johnson PJ. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol 2000; 62: 299-307 [PMID: 11055239]
29. Hui CK, Cheung WW, Zhang HY, Au WY, Yueng YH, Leung AY, Leung N, Luk JM, Lie AK, Kwong YL, Liang R, Lau GK. Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. Gastroenterology 2006; 131: 59-68 [PMID: 16831590 DOI: 10.1053/j.gastro.2006.04.015]
30. Vento S, Cainelli F, Longhi MS. Reactivation of replication of hepatitis B and C viruses after immunosuppressive therapy: an unresolved issue. Lancet Oncol 2002; 3: 333-340 [PMID: 12107020 DOI: 10.1016/S1470-2045(02)00773-8]
31. Yeo W, Chan TC, Leung NW, Lam WY, Mo FK, Chu MT, Chan HL, Hui EP, Lei KI, Mok TS, Chan PK. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol 2009; 27: 605-611 [PMID: 19075267 DOI: 10.1200/JCO.2008.18.0182]
32. Yeo W, Zee B, Zhong S, Chan PK, Wong WL, Ho WM, Lam KC, Johnson PJ. Comprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy. Br J Cancer 2004; 90: 1306-1311 [PMID: 15054446 DOI: 10.1038/ sj.bjc.6601699]
33. Huang YH, Hsiao LT, Hong YC, Chiou TJ, Yu YB, Gau JP, Liu CY, Yang MH, Tzeng CH, Lee PC, Lin HC, Lee SD. Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B. J Clin Oncol 2013; 31: 2765-2772 [PMID: 23775967 DOI: 10.1200/ JCO.2012.48.5938]
34. Sera T, Hiasa Y, Michitaka K, Konishi I, Matsuura K, Tokumoto Y, Matsuura B, Kajiwara T, Masumoto T, Horiike N, Onji M. Anti-HBs-positive liver failure due to hepatitis B virus reactivation induced by rituximab. Intern Med 2006; 45: 721-724 [PMID: 16819252 DOI: 10.2169/internalmedicine.45.1590]
35. Umemura T, Kiyosawa K. Fatal HBV reactivation in a subject with anti-HBs and anti-HBc. Intern Med 2006; 45: 747-748 [PMID: 16847362 DOI: 10.2169/internalmedicine.45.0158]
36. Loomba R, Rowley A, Wesley R, Liang TJ, Hoofnagle JH, Pucino F, Csako G. Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med 2008; 148: 519-528 [PMID: 18378948 DOI: 10.7326/0003-4819-148-7-200804010-00008]
37. Lau GK, Yiu HH, Fong DY, Cheng HC, Au WY, Lai LS, Cheung M, Zhang HY, Lie A, Ngan R, Liang R. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology 2003; 125: 1742-1749 [PMID: 14724827]
38. Silvestri F, Ermacora A, Sperotto A, Patriarca F, Zaja F, Damiani D, Fanin R, Baccarani M. Lamivudine allows completion of chemotherapy in lymphoma patients with hepatitis B reactivation. Br J Haematol 2000; 108: 394-396 [PMID: 10691871 DOI: 10.1046/j.1365-2141.2000.01847.x]
39. Shibolet O, Ilan Y, Gillis S, Hubert A, Shouval D, Safadi R. Lamivudine therapy for prevention of immunosuppressiveinduced hepatitis B virus reactivation in hepatitis B surface antigen carriers. Blood 2002; 100: 391-396 [PMID: 12091327 DOI: 10.1182/blood.V100.2.391]
40. Yeo W, Ho WM, Hui P, Chan PK, Lam KC, Lee JJ, Johnson PJ. Use of lamivudine to prevent hepatitis B virus reactivation during chemotherapy in breast cancer patients. Breast Cancer Res Treat 2004; 88: 209-215 [PMID: 15609123 DOI: 10.1007/s10549-004-0725-1]
41. He YF, Li YH, Wang FH, Jiang WQ, Xu RH, Sun XF, Xia ZJ, Huang HQ, Lin TY, Zhang L, Bao SP, He YJ, Guan ZZ. The effectiveness of lamivudine in preventing hepatitis B viral reactivation in rituximab-containing regimen for lymphoma. Ann Hematol 2008; 87: 481-485 [PMID: 18299831 DOI: 10.1007/s00277-008-0454-3]
42. Mimidis K, Tsatalas C, Margaritis D, Martinis G, Spanoudakis E, Kotsiou S, Kartalis G, Bourikas G. Efficacy of Lami-vudine in patients with hematologic malignancies receiving chemotherapy and precore mutant chronic active hepatitis B. Acta Haematol 2002; 107: 49-51 [PMID: 11818674 DOI: 10.1159/000046631]
43. Hamaki T, Kami M, Kusumi E, Ueyama J, Miyakoshi S, Morinaga S, Mutou Y. Prophylaxis of hepatitis B reactivation using lamivudine in a patient receiving rituximab. Am J Hematol 2001; 68: 292-294 [PMID: 11754421 DOI: 10.1002/ ajh.10043]
44. Kami M, Hamaki T, Murashige N, Kishi Y, Kusumi E, Yuji K, Miyakoshi S, Ueyama J, Morinaga S, Mutou Y. Safety of rituximab in lymphoma patients with hepatitis B or hepatitis C virus infection. Hematol J 2003; 4: 159-162 [PMID: 12750737]
45. Lok AS, McMahon BJ. Chronic hepatitis B: update of recommendations. Hepatology 2004; 39: 857-861 [PMID: 14999707 DOI: 10.1002/hep.20110]
46. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2001; 34: 1225-1241 [PMID: 11732013 DOI: 10.1053/jhep.2001.29401]
47. Pelizzari AM, Motta M, Cariani E, Turconi P, Borlenghi E, Rossi G. Frequency of hepatitis B virus mutant in asymptomatic hepatitis B virus carriers receiving prophylactic lamivudine during chemotherapy for hematologic malignancies. Hematol J 2004; 5: 325-328 [PMID: 15297849 DOI: 10.1038/sj.thj.6200396]
48. Picardi M, Pane F, Quintarelli C, De Renzo A, Del Giudice A, De Divitiis B, Persico M, Ciancia R, Salvatore F, Rotoli B. Hepatitis B virus reactivation after fludarabine-based regimens for indolent non-Hodgkin's lymphomas: high prevalence of acquired viral genomic mutations. Haematologica 2003; 88: 1296-1303 [PMID: 14607759]
49. Miyagawa M, Minami M, Fujii K, Sendo R, Mori K, Shimizu D, Nakajima T, Yasui K, Itoh Y, Taniwaki M, Okanoue T, Yoshikawa T. Molecular characterization of a variant virus that caused de novo hepatitis B without elevation of hepatitis B surface antigen after chemotherapy with rituximab. J Med Virol 2008; 80: 2069-2078 [PMID: 19040281 DOI: 10.1002/jmv.21311]
50. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007; 45: 507-539 [PMID: 17256718 DOI: 10.1002/hep.21513]
51. Liaw YF, Leung N, Guan R, Lau GK, Merican I, McCaughan G, Gane E, Kao JH, Omata M. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update. Liver Int 2005; 25: 472-489 [PMID: 15910483 DOI: 10.1111/j.1478-3231.2005.01134.x]
52. European Association For The Study Of The Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009; 50: 227-242 [PMID: 19054588 DOI: 10.1016/j.jhep.2008.10.001]
53. Hu KQ. Occult hepatitis B virus infection and its clinical implications. J Viral Hepat 2002; 9: 243-257 [PMID: 12081601 DOI: 10.1046/j.1365-2893.2002.00344.x]
54. Yeo W, Lam KC, Zee B, Chan PS, Mo FK, Ho WM, Wong WL, Leung TW, Chan AT, Ma B, Mok TS, Johnson PJ. Hepatitis B reactivation in patients with hepatocellular carcinoma undergoing systemic chemotherapy. Ann Oncol 2004; 15: 1661-1666 [PMID: 15520068 DOI: 10.1093/annonc/mdh430]
55. Awerkiew S, Däumer M, Reiser M, Wend UC, Pfister H, Kaiser R, Willems WR, Gerlich WH. Reactivation of an occult hepatitis B virus escape mutant in an anti-HBs positive, anti-HBc negative lymphoma patient. J Clin Virol 2007; 38: 83-86 [PMID: 17134939 DOI: 10.1016/j.jcv.2006.10.006]
56. Onozawa M, Hashino S, Izumiyama K, Kahata K, Chuma M, Mori A, Kondo T, Toyoshima N, Ota S, Kobayashi S, Hige S, Toubai T, Tanaka J, Imamura M, Asaka M. Progressive disappearance of anti-hepatitis B surface antigen antibody and reverse seroconversion after allogeneic hematopoietic stem cell transplantation in patients with previous hepatitis B virus infection. Transplantation 2005; 79: 616-619 [PMID: 15753855 DOI: 10.1097/01.TP.0000151661.52601.FB]
57. Pei SN, Ma MC, Wang MC, Kuo CY, Rau KM, Su CY, Chen CH. Analysis of hepatitis B surface antibody titers in B cell lymphoma patients after rituximab therapy. Ann Hematol 2012; 91: 1007-1012 [PMID: 22273839 DOI: 10.1007/ s00277-012-1405-6]
58. Tsutsumi Y, Ogasawara R, Miyashita N, Tanaka J, Asaka M, Imamura M. HBV reactivation in malignant lymphoma patients treated with rituximab and bendamustine. Int J Hematol 2012; 95: 588-591 [PMID: 22419099 DOI: 10.1007/ s12185-012-1050-9]
59. Allain JP. Occult hepatitis B virus infection. Transfus Clin Biol 2004; 11: 18-25 [PMID: 14980545 DOI: 10.1016/ j.tracli.2003.11.007]
60. Liang R. How I treat and monitor viral hepatitis B infection in patients receiving intensive immunosuppressive therapies or undergoing hematopoietic stem cell transplantatio. Blood 2009; 113: 3147-3153 [PMID: 19144986 DOI: 10.1182/ blood-2008-10-163493]
61. Christensen PB, Clausen MR, Krarup H, Laursen AL, Schlichting P, Weis N. Treatment for hepatitis B virus (HBV) and hepatitis C virus (HCV) infection - Danish national guidelines 2011. Dan Med J 2012; 59: C4465 [PMID: 22677253]
62. Gossmann J, Scheuermann EH, Kachel HG, Geiger H, Hauser IA. Reactivation of hepatitis B two years after rituximab therapy in a renal transplant patient with recurrent focal segmental glomerulosclerosis: a note of caution. Clin Transplant 2009; 23: 431-434 [PMID: 19077081 DOI: 10.1111/ j.1399-0012.2008.00936.x]
63. Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R, Newman RA, Hanna N, Anderson DR. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994; 83: 435-445 [PMID: 7506951]
64. Yeo W, Johnson PJ. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology 2006; 43: 209-220 [PMID: 16440366 DOI: 10.1002/hep.21051]
65. Papatheodoridis GV, Manolakopoulos S, Dusheiko G, Archimandritis AJ. Therapeutic strategies in the management of patients with chronic hepatitis B virus infection. Lancet Infect Dis 2008; 8: 167-178 [PMID: 18053766 DOI: 10.1016/ S1473-3099]
66. McLaughlin P, Grillo-López AJ, Link BK, Levy R, Czuczman MS, Williams ME, Heyman MR, Bence-Bruckler I, White CA, Cabanillas F, Jain V, Ho AD, Lister J, Wey K, Shen D, Dallaire BK. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16: 2825-2833 [PMID: 9704735]
67. Tobinai K, Kobayashi Y, Narabayashi M, Ogura M, Kagami Y, Morishima Y, Ohtsu T, Igarashi T, Sasaki Y, Kinoshita T, Murate T. Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) in relapsed B-cell lymphoma. The IDEC-C2B8 Study Group. Ann Oncol 1998; 9: 527-534 [PMID: 9653494 DOI: 10.1023/A: 1008265313133]
68. Igarashi T, Ohtsu T, Fujii H, Sasaki Y, Morishima Y, Ogura M, Kagami Y, Kinoshita T, Kasai M, Kiyama Y, Kobayashi Y, Tobinai K. Re-treatment of relapsed indolent B-cell lymphoma with rituximab. Int J Hematol 2001; 73: 213-221 [PMID: 11372734 DOI: 10.1007/BF02981940]
69. Dai MS, Chao TY, Kao WY, Shyu RY, Liu TM. Delayed hepatitis B virus reactivation after cessation of preemptive lamivudine in lymphoma patients treated with rituximab plus CHOP. Ann Hematol 2004; 83: 769-774 [PMID: 15338194 DOI: 10.1007/s00277-004-0899-y]
70. Garcia-Rodriguez MJ, Canales MA, Hernandez-Maraver D, Hernandez-Navarro F. Late reactivation of resolved hepatitis B virus infection: an increasing complication post rituximab-based regimens treatment? Am J Hematol 2008; 83: 673-675 [PMID: 18528824 DOI: 10.1002/ajh.21214]
71. Perceau G, Diris N, Estines O, Derancourt C, Lévy S, Bernard P. Late lethal hepatitis B virus reactivation after rituximab treatment of low-grade cutaneous B-cell lymphoma. Br J Dermatol 2006; 155: 1053-1056 [PMID: 17034541 DOI: 10.1111/j.1365-2133.2006.07451.x]
72. Fung SK, Andreone P, Han SH, Rajender Reddy K, Regev A, Keeffe EB, Hussain M, Cursaro C, Richtmyer P, Marrero JA, Lok AS. Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation. J Hepatol 2005; 43: 937-943 [PMID: 16168522 DOI: 10.1016/ j.jhep.2005.05.037]
73. Peters MG, Hann Hw Hw, Martin P, Heathcote EJ, Buggisch P, Rubin R, Bourliere M, Kowdley K, Trepo C, Gray Df Df, Sullivan M, Kleber K, Ebrahimi R, Xiong S, Brosgart CL. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 2004; 126: 91-101 [PMID: 14699491 DOI: 10.1053/j.gastro.2003.10.051]
74. Pérez-Roldán F, González-Carro P, Villafáñez-García MC.Adefovir dipivoxil for chemotherapy-induced activation of hepatitis B virus infection. N Engl J Med 2005; 352: 310-311 [PMID: 15659742 DOI: 10.1056/NEJM200501203520324]
75. Tillmann HL, Wedemeyer H, Manns MP. Treatment of hepatitis B in special patient groups: hemodialysis, heart and renal transplant, fulminant hepatitis, hepatitis B virus reactivation. J Hepatol 2003; 39 Suppl 1: S206-S211 [PMID: 14708705 DOI: 10.1016/S0168-8278(03)00364-7]
76. Vigna-Perez M, Hernández-Castro B, Paredes-Saharopulos O, Portales-Pérez D, Baranda L, Abud-Mendoza C, González-Amaro R. Clinical and immunological effects of Rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study. Arthritis Res Ther 2006; 8: R83 [PMID: 16677395 DOI: 10.1186/ar1954]
77. Méndez-Navarro J, Corey KE, Zheng H, Barlow LL, Jang JY, Lin W, Zhao H, Shao RX, McAfee SL, Chung RT. Hepatitis B screening, prophylaxis and re-activation in the era of rituximab-based chemotherapy. Liver Int 2011; 31: 330-339 [PMID: 20738779 DOI: 10.1111/j.1478-3231.2010.02332.x]